aon-d21
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 3, 2021 (NCT05018403)
Timeline
Indications
Mechanism of action
C5AR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05962606 | Phase 2 | Oct 30, 2023 | Aptarion Biotech AG |
| NCT05343819 | Phase 1 | Apr 12, 2022 | Aptarion Biotech AG, Nuvisan Pharma Services |
| NCT05018403 | Phase 1 | Aug 3, 2021 | Aptarion Biotech AG, Nuvisan Pharma Services |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptarion Biotech AG | For profit | 3 | 3 | 2 | 2021 |
| Nuvisan Pharma Services | For profit | 2 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1